🎖️أهم مقالات بحثية مبتكرة في عام ٢٠٢٤🎖️
[ #الجزء_الأول ]
⭕ لقاح #Butrantan-Dengu الحي و الموهن و المتكافئ عند الأطفال و البالغين للوقايه من ( #حمي_الضنك ) البادئه فـ الإنتشار حالياً في شمال مصر.
⭕ المرحلة ٣ (تجربة عشوائية خاضعة للرقابة) لـ #ريزميتروم #Resmetirom في مرض NASH لعلاج ( #تليف_الكبد).
⭕ دواء #أوماليزوماب #Omalizumab لعلاج ( #حساسية_الغذاء المتعددة
الآثار).
⭕ دواء #لسيماجلوتيد #Semaglutide على أمراض ( #الكلي_المزمنة) لدى ( مرضى #السكري من النوع ٢).
Firsts are worth celebrating. In this case, the cause for celebration is especially great. Late this week,
@us_fda approved
#resmetirom to be the first ever treatment for
#MASH with
#fibrosis.
This brings the promise of much progress to come.
https://conscienhealth.org/2024/03/fda-approves-resmetirom-first-ever-for-mash-with-fibrosis/
FDA Approves Resmetirom: First Ever for MASH with Fibrosis - ConscienHealth
Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis, bringing the promise of much progress to come.
Rezdiffra (resmetirom): FDA Approves First Treatment for Liver Scarring Due to Fatty Liver Disease
Rezdiffra (resmetirom) has been approved by the FDA of the USA for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH)...........
#fattyliver #FDA #liverdisease #nonalcoholicfattyliver #Resmetirom #Rezdiffra
SCIEU Team
https://www.scientificeuropean.co.uk/medicine/rezdiffra-resmetirom-fda-approves-first-treatment-for-liver-scarring-due-to-fatty-liver-disease/
Rezdiffra (resmetirom): FDA Approves First Treatment for Liver Scarring Due to Fatty Liver Disease
Rezdiffra (resmetirom) has been approved by the FDA of the USA for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate
Are we finally seeing progress in the development of better treatment options for
#MASH? Topline results with
#survodutide on top of pivotal results with
#resmetirom in NEJM suggest we are.
https://conscienhealth.org/2024/02/progress-reported-in-mash-with-survodutide/
Progress Reported in MASH with Survodutide - ConscienHealth
Topline results for survodutide in MASH gives us one more reason to believe progress is coming in treatment options for this liver disease.
Resmetirom Improved Liver Fat and Fibrosis in Late-Stage NASH Trial
Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.
Marzouk Al-Khawaga,. MD
ConscienHealth
Scientific European
Liz Highleyman